tradingkey.logo

Elutia Inc

ELUT
View Detailed Chart

1.090USD

+0.010+0.93%
Close 09/19, 16:00ETQuotes delayed by 15 min
46.21MMarket Cap
LossP/E TTM

Elutia Inc

1.090

+0.010+0.93%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.93%

5 Days

-14.84%

1 Month

-46.04%

6 Months

-66.77%

Year to Date

-70.86%

1 Year

-71.54%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
74 / 175
Overall Ranking
223 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
5.500
Target Price
+409.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.38M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 63.99.
Fairly Valued
The company’s latest PE is -3.63, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 29.13M shares, increasing 15.28% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.18M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Ticker SymbolELUT
CompanyElutia Inc
CEODr. C. Randal (Randal) Mills, Ph.D.
Websitehttps://elutia.com/
KeyAI